| Outcome Measures: |
Primary: Changes in cognitive function from baseline to 12 weeks, MMSE, 0 week, 12 week | Secondary: Changes of metabolic parameters from baseline to 12 weeks, Systolic and diastolic blood pressure, 0 week, 12 week|Changes of Alzheimer's disease-associated serum markers from baseline to 12 weeks, Aβ42, 0 week, 12 week|Changes of Alzheimer's disease-associated serum markers from baseline to 12 weeks, tau, 0 week, 12 week|Changes of Alzheimer's disease-associated serum markers from baseline to 12 weeks, P-tau, 0 week, 12 week|Changes of Alzheimer's disease-associated serum markers from baseline to 12 weeks, TDP-43, 0 week, 12 week|Changes of Alzheimer's disease-associated serum markers from baseline to 12 weeks, IL-6, 0 week, 12 week|Changes of Alzheimer's disease-associated serum markers from baseline to 12 weeks, IL-8, 0 week, 12 week|Changes of Alzheimer's disease-associated serum markers from baseline to 12 weeks, TNF-a, 0 week, 12 week|Changes of metabolic parameters from baseline to 12 weeks, HbA1c, 0 week, 12 week|Changes of metabolic parameters from baseline to 12 weeks, fasting plasma glucose, 0 week, 12 week|Changes of metabolic parameters from baseline to 12 weeks, body mass index, 0 week, 12 week|Changes of metabolic parameters from baseline to 12 weeks, lipid profile, 0 week, 12 week|Changes of metabolic parameters from baseline to 12 weeks, waist circumference, 0 week, 12 week
|
